M2BPGi Emerges as a Versatile Serum Marker for Liver Fibrosis and HCC Risk
Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum biomarker that predicts liver fibrosis stage across chronic hepatitis B and C, NAFLD, and other liver diseases, while also forecasting hepatocellular carcinoma development and prognosis. Importantly, M2BPGi thresholds vary by disease aetiology and treatment status, requiring context-specific cut-off values for optimal diagnostic performance.
The original study
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.
- Authors
- Tamaki N, Kurosaki M, Loomba R, Izumi N
- Journal
- Annals of laboratory medicine
- Type
- Journal Article, Review
- PMID
- 32829576
Original abstract
An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review, we discuss the role of M2BPGi in diagnosing liver fibrosis in chronic hepatitis B and C, chronic hepatitis C after sustained virologic response (SVR), and nonalcoholic fatty liver disease (NAFLD). M2BPGi predicts not only liver fibrosis but also the hepatocellular carcinoma (HCC) development and prognosis in patients with chronic hepatitis B and C, chronic hepatitis C after SVR, NAFLD, and other chronic liver diseases. M2BPGi can also be used to evaluate liver function and prognosis in patients with cirrhosis. M2BPGi levels vary depending on the etiology and the presence or absence of treatment. Therefore, the threshold of M2BPGi for diagnosing liver fibrosis and predicting HCC development has to be adjusted according to the background and treatment status.